These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34600591)

  • 1. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy.
    Azzari C; Baraldi E; Bonanni P; Bozzola E; Coscia A; Lanari M; Manzoni P; Mazzone T; Sandri F; Checcucci Lisi G; Parisi S; Piacentini G; Mosca F
    Ital J Pediatr; 2021 Oct; 47(1):198. PubMed ID: 34600591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSV disease in infants and young children: Can we see a brighter future?
    Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
    Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D; Schonfeld T; Amir J;
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
    Ektare V; Lang J; Choi Y; Finelli L
    Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RSV Lower Respiratory Tract Illness in Infants of Low- and Middle-income Countries.
    Laudanno SL; Sánchez Yanotti CI; Polack FP
    Acta Med Acad; 2020 Aug; 49(2):191-197. PubMed ID: 33189124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?
    Baldassarre ME; Loconsole D; Centrone F; Caselli D; Martire B; Quartulli L; Acquafredda A; D'Amato G; Maffei G; Latorre G; Riganti A; Di Noia M; Chironna M; Laforgia N
    Ital J Pediatr; 2023 Jun; 49(1):66. PubMed ID: 37280662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.
    Fortunato F; Campanozzi A; Maffei G; Arena F; Carri VD; Rollo T; Lopalco PL; Martinelli D
    Ital J Pediatr; 2024 Mar; 50(1):45. PubMed ID: 38454523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy.
    Dovizio M; Veronesi C; Bartolini F; Cavaliere A; Grego S; Pagliaro R; Procacci C; Ubertazzo L; Bertizzolo L; Muzii B; Parisi S; Perrone V; Baraldi E; Bozzola E; Mosca F; Esposti LD
    Ital J Pediatr; 2024 Mar; 50(1):57. PubMed ID: 38528616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
    Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
    Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.
    Goddard NL; Cooke MC; Gupta RK; Nguyen-Van-Tam JS
    Epidemiol Infect; 2007 Jan; 135(1):159-62. PubMed ID: 16753078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.